142 related articles for article (PubMed ID: 33865565)
1. Predictive factors of radioiodine therapy failure in Graves' Disease: A meta-analysis.
Shalaby M; Hadedeya D; Toraih EA; Razavi MA; Lee GS; Hussein MH; Weidenhaft MC; Serou MJ; Ibraheem K; Abdelgawad M; Kandil E
Am J Surg; 2022 Feb; 223(2):287-296. PubMed ID: 33865565
[TBL] [Abstract][Full Text] [Related]
2. The effect of propylthiouracil on subsequent radioactive iodine therapy in Graves' disease.
Hancock LD; Tuttle RM; LeMar H; Bauman J; Patience T
Clin Endocrinol (Oxf); 1997 Oct; 47(4):425-30. PubMed ID: 9404440
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factor analysis in 325 patients with Graves' disease treated with radioiodine therapy.
Yang D; Xue J; Ma W; Liu F; Fan Y; Rong J; Yang A; Yu Y
Nucl Med Commun; 2018 Jan; 39(1):16-21. PubMed ID: 29040161
[TBL] [Abstract][Full Text] [Related]
4. Predictive factors for early hypothyroidism following the radioactive iodine therapy in Graves' disease patients.
Hu RT; Liu DS; Li B
BMC Endocr Disord; 2020 May; 20(1):76. PubMed ID: 32471411
[TBL] [Abstract][Full Text] [Related]
5. Predictive factors for the outcomes of Graves' disease patients with radioactive iodine (131I) treatment.
Xing YZ; Zhang K; Jin G
Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31840740
[TBL] [Abstract][Full Text] [Related]
6. Radioiodine therapy in Graves' disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy.
Sabri O; Zimny M; Schreckenberger M; Reinartz P; Ostwald E; Buell U
Thyroid; 1999 Dec; 9(12):1181-8. PubMed ID: 10646656
[TBL] [Abstract][Full Text] [Related]
7. Radioactive iodine ablation therapy: a viable option in the management of Graves' disease in Nigeria.
Adedapo KS; Fadiji IO; Orunmuyi AT; Onimode Y; Osifo BO
Afr J Med Med Sci; 2012 Dec; 41 Suppl():193-6. PubMed ID: 23678656
[TBL] [Abstract][Full Text] [Related]
8.
Zhao L; Zhang W; Xin Y; Wen Q; Bail L; Guan F; Bin J
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(6):349-353. PubMed ID: 30413358
[TBL] [Abstract][Full Text] [Related]
9. Radioiodine treatment in pediatric Graves' disease and thyroid carcinoma.
Yuan L; Yang J
J Pediatr Endocrinol Metab; 2011; 24(11-12):877-83. PubMed ID: 22308835
[TBL] [Abstract][Full Text] [Related]
10. [Radioiodine versus surgery in the treatment of Graves' hyperthyroidism].
Jukić T; Stanicić J; Petric V; Kusić Z
Lijec Vjesn; 2010; 132(11-12):355-60. PubMed ID: 21294325
[TBL] [Abstract][Full Text] [Related]
11. Radioactive iodine therapy for pediatric Graves' disease: a single-center experience over a 10-year period.
Kaplowitz PB; Jiang J; Vaidyanathan P
J Pediatr Endocrinol Metab; 2020 Mar; 33(3):383-389. PubMed ID: 31603857
[TBL] [Abstract][Full Text] [Related]
12. Radioiodine therapy in Graves' disease: is it possible to predict outcome before therapy?
Isgoren S; Daglioz Gorur G; Demir H; Berk F
Nucl Med Commun; 2012 Aug; 33(8):859-63. PubMed ID: 22669051
[TBL] [Abstract][Full Text] [Related]
13. [Influence of glucocorticoid therapy on intratherapeutic biodistribution of 131I radioiodine therapy in Graves' disease].
Halstenberg J; Kranert WT; Korkusuz H; Mayer A; Ackermann H; Grünwald F; Happel C
Nuklearmedizin; 2018 Apr; 57(2):43-49. PubMed ID: 29590674
[TBL] [Abstract][Full Text] [Related]
14. A predictive mathematical model for the calculation of the final mass of Graves' disease thyroids treated with 131I.
Traino AC; Di Martino F; Grosso M; Monzani F; Dardano A; Caraccio N; Mariani G; Lazzeri M
Phys Med Biol; 2005 May; 50(9):2181-91. PubMed ID: 15843745
[TBL] [Abstract][Full Text] [Related]
15. Discriminant factors affecting early outcome of radioiodine treatment for Graves' disease.
Kung AW; Choi P; Lam KS; Pun KK; Wang C; Yeung RT
Clin Radiol; 1990 Jul; 42(1):52-4. PubMed ID: 2390837
[TBL] [Abstract][Full Text] [Related]
16. Influence of high tissue-absorbed dose on anti-thyroid antibodies in radioiodine therapy of Graves' disease patients.
Listewnik MH; Piwowarska-Bilska H; Jasiakiewicz K; Birkenfeld B
Adv Clin Exp Med; 2021 Sep; 30(9):913-921. PubMed ID: 34418335
[TBL] [Abstract][Full Text] [Related]
17. Antithyroid drugs as a factor influencing the outcome of radioiodine therapy in Graves' disease and toxic nodular goitre?
Körber C; Schneider P; Körber-Hafner N; Hänscheid H; Reiners C
Eur J Nucl Med; 2001 Sep; 28(9):1360-4. PubMed ID: 11585295
[TBL] [Abstract][Full Text] [Related]
18. The effect of radioiodine treatment on the characteristics of TRAb in Graves' disease.
Fang Y; Du WH; Zhang CX; Zhao SX; Song HD; Gao GQ; Dong M
BMC Endocr Disord; 2021 Nov; 21(1):238. PubMed ID: 34847904
[TBL] [Abstract][Full Text] [Related]
19. Vitamin B12 levels are not affected by radioiodine ablation of the thyroid.
Potham SK; Vaikkakara S; Sachan A; Rao SP; Kalawat TC; Ravi P; Sunil E; Rajitha D; Arun M; Sailaja A
Endocr Regul; 2014 Apr; 48(2):77-85. PubMed ID: 24824803
[TBL] [Abstract][Full Text] [Related]
20. Age moderates the associations between TRAbs, free T3 and outcomes of Graves' disease patients with radioactive iodine treatment.
Lu L; Gao C; Zhang N
Clin Endocrinol (Oxf); 2021 Feb; 94(2):303-309. PubMed ID: 32734611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
